Ocular Therapeutix™ Reports Third Quarter 2025 Financial Results and Business Highlights Recent Investor Day highlighted how AXPAXLI™ is positioned to redefine retina based on potential superiority label, market expansion, and immediate adoptability Announced today that SOL-R achieved target randomization of 555 subjects Exceptional execution and retention in AXPAXLI wet AMD registrational program continue with topline data on track for SOL-1 in 1Q 2026 and SOL-R in 1H 2027 Registrational HELIOS program for AXPAXLI in NPDR expected to begin imminently using a novel primary endpoint Cash...
Ocular Therapeutix™ Achieves Target Randomization of 555 Subjects in SOL-R SOL-R, the second registrational trial of AXPAXLI™ in wet AMD, remains on track for topline data in 1H 2027 Together with SOL-1, these complementary trials are expected to form the basis of a potential NDA submission for AXPAXLI in wet AMD BEDFORD, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that its SOL-R registrational trial of AXPAXLI™ (also known as OTX-TKI) in...
Ocular Therapeutix™ to Report Third Quarter 2025 Financial Results on November 4, 2025 BEDFORD, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Tuesday, November 4, 2025 at 8:00 AM ET to discuss recent business progress and financial results for the third quarter ended September 30, 2025. Conference Call and Webcast Information: Date: Tuesday, November 4, 2025, at 8:00 AM ET Participant ...
A director at Agree Realty Corp bought 25,154 shares at 70.410USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.